glp 1 agonist muscle loss Weighing the risk of GLP-1 treatment in older adults: Should we be concerned about sarcopenic obesity? Using glp-1 receptor agonists for

Clinical evidence, encompassing trials, epidemiological investigations, and findings from animal toxicology and histological studies, has revealed potential associations between GLP-1RAs and the risk of neuroendocrine tumors and exocrine pancreatic dysplasia, with some evidence suggesting an increased risk of pancreatic cancer [6]

132 Glutamate receptors, including the amino-3-hydroxy-5-methyl-4-isoxazolepro-pionicacid (AMPA) and N-methyl-D-aspartate (NMDA) receptors, mediate excitatory synaptic transmission in the CNS, and its expression in the postsynaptic membrane is associated with LTP and LTD and is involved in the regulation of learning and memory activities

Obesity and cancer: A current overview of epidemiology, pathogenesis, outcomes, and management

Accessed 2025 Apr 29

Brain Behav (2020) 10(3):e01505

doi: 10.1016/S0140-6736(16)31679-8 Erratum in: Lancet